Bliss GVS Pharma Limited (BLISSGVS.NS)
INR 169.0
(0.87%)
INR 169.0
(0.87%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 1.51 Billion | 343.13 Million | 1.35 Billion | 639.69 Million | 452.79 Million | 399.5 Million |
| Net Income | 754.54 Million | 1.06 Billion | 1.27 Billion | 1.04 Billion | 1.28 Billion | 1.81 Billion |
| Depreciation & Amortization | 263.79 Million | 186.73 Million | 173.3 Million | 172.29 Million | 125.89 Million | 89.43 Million |
| Deferred income taxes | - | -182.66 Million | -141.05 Million | -70.9 Million | - | - |
| Stock-based compensation | 38.15 Million | 39.04 Million | 57.07 Million | 98.37 Million | - | - |
| Change in working capital | 30.41 Million | -851.19 Million | 733.72 Million | -578.86 Million | -692.21 Million | -1.83 Billion |
| Other non-cash items | 1.91 Billion | 90.5 Million | -745.85 Million | -22.48 Million | -270.53 Million | 321.66 Million |
| Investing Cash Flow | -1.37 Billion | -77.5 Million | -929.75 Million | -469.91 Million | -489.48 Million | -735.18 Million |
| Investments in PPE | -283.29 Million | -937.99 Million | -740.03 Million | -91.24 Million | -603.14 Million | -437.68 Million |
| Acquisitions | 6.03 Million | 139.25 Million | 10.67 Million | 4.2 Million | 8.55 Million | 57.48 Million |
| Investment purchases | -1.15 Billion | -77.07 Million | -22.3 Million | -436.88 Million | -32.21 Million | -396.82 Million |
| Sales/Maturities of investments | 51.06 Million | 22.49 Million | -10.67 Million | 432.68 Million | 23.66 Million | 339.34 Million |
| Other Investing Activities | -1.04 Billion | 775.8 Million | -167.41 Million | -378.66 Million | 113.66 Million | -297.5 Million |
| Financing Cash Flow | -147.92 Million | -249.38 Million | -237.3 Million | -207.98 Million | -38.26 Million | 168.31 Million |
| Debt repayment | -88.95 Million | -538.95 Million | -263.61 Million | -163.41 Million | -135.55 Million | -186.78 Million |
| Dividends payments | -53.94 Million | -54.37 Million | -53.26 Million | -55.49 Million | -125 Million | -82.37 Million |
| Common Stock Repurchased | - | 518.53 Million | 240.76 Million | - | - | - |
| Common Stock Issuance | 23.49 Million | 20.41 Million | 22.84 Million | - | - | - |
| Other Financing Activities | 355 Thousand | -195.01 Million | -184.03 Million | 10.93 Million | 222.28 Million | 437.46 Million |
| Accounts receivables | -445.18 Million | -149.98 Million | 512.9 Million | 629.25 Million | -785.31 Million | -1.82 Billion |
| Accounts payables | -251 Million | -63.16 Million | 183.44 Million | -146.76 Million | 128.41 Million | 205.15 Million |
| Inventory | -224.21 Million | 150.03 Million | -290.96 Million | -268.01 Million | 8.05 Million | -183.33 Million |
| Other working capital | 950.82 Million | -788.08 Million | 328.34 Million | -793.34 Million | -43.37 Million | -30.86 Million |
| Cash at beginning of period | 645.41 Million | 219.87 Million | 131.34 Million | 153.39 Million | 150.39 Million | 369.49 Million |
| Cash at end of period | 2.15 Billion | 250.06 Million | 219.87 Million | 131.34 Million | 153.42 Million | 150.39 Million |
| Capital Expenditure | -283.29 Million | -937.99 Million | -740.03 Million | -91.24 Million | -603.14 Million | -437.68 Million |
| Effect of forex changes on cash | -1.5 Million | 13.95 Million | -99.22 Million | 16.14 Million | 77.46 Million | -51.72 Million |
| Net cash flow / Change in cash | 1.51 Billion | 30.19 Million | 88.52 Million | -22.05 Million | 3.03 Million | -219.1 Million |
| Free Cash Flow | 1.23 Billion | -594.85 Million | 614.77 Million | 548.45 Million | -150.35 Million | -38.18 Million |
| Breakdown | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 206.97 Million | 754.54 Million | -91.47 Million | 276.1 Million | 423.06 Million | 146.85 Million |
| Depreciation & Amortization | - | 263.79 Million | - | 69.53 Million | 63.91 Million | 61.88 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 12.94 Million | 38.15 Million | 38.15 Million | - | 10.43 Million | 11.54 Million |
| Change in working capital | - | 30.41 Million | - | - | - | - |
| Other non-cash items | -219.91 Million | 1.91 Billion | 53.32 Million | -276.1 Million | -433.49 Million | -158.39 Million |
| Investing Cash Flow | - | -1.37 Billion | - | - | - | - |
| Investments in PPE | - | -283.29 Million | - | - | - | - |
| Acquisitions | - | 6.03 Million | - | - | - | - |
| Investment purchases | - | -1.15 Billion | - | - | - | - |
| Sales/Maturities of investments | - | 51.06 Million | - | - | - | - |
| Other Investing Activities | - | -1.04 Billion | - | - | - | - |
| Financing Cash Flow | - | -147.92 Million | - | - | - | - |
| Debt repayment | - | -88.95 Million | - | - | - | - |
| Dividends payments | - | -53.94 Million | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 23.49 Million | - | - | - | - |
| Other Financing Activities | - | 355 Thousand | - | - | - | - |
| Accounts receivables | - | -445.18 Million | - | - | - | - |
| Accounts payables | - | -251 Million | - | - | - | - |
| Inventory | - | -224.21 Million | - | - | - | - |
| Other working capital | - | 950.82 Million | - | - | - | - |
| Cash at beginning of period | - | 645.41 Million | - | 1.61 Billion | 1.48 Billion | 645.41 Million |
| Cash at end of period | - | 2.15 Billion | - | 1.75 Billion | 1.61 Billion | 11.54 Million |
| Capital Expenditure | - | -283.29 Million | - | - | - | - |
| Effect of forex changes on cash | - | -1.5 Million | - | - | - | - |
| Net cash flow / Change in cash | - | 1.51 Billion | - | 139.07 Million | 138.25 Million | -633.87 Million |
| Free Cash Flow | - | 1.23 Billion | - | 139.07 Million | 138.25 Million | 11.54 Million |
SPX
0QOB
RSWM
MDEVF
GXUSF
CWK